What You Should Be Reading: : Hepatitis

FDA Issues Black Box Warning for DAAs

Sunday, December 17, 2017   (0 Comments)
Posted by: Admin
Share |

The U.S. Food and Drug Administration (FDA) has issued a black box warning for the DAAs used in the treatment of chronic hepatitis C virus. There have been reports in the literature and to the FDA of hepatitis B virus reactivation and several cases of fulminant hepatitis B in patients who are co-infected with hepatitis C virus and hepatitis B virus who begin anti-HCV DAA treatment. U.S. hepatitis C guidelines have been updated to include recommendations for hepatitis B virus testing prior initiation of DAA treatment and suppressive therapy for hepatitis B virus during DAA treatment for individuals who meet HBV treatment criteria.  




Association Management Software Powered by YourMembership  ::  Legal